help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Endocrinology, doi:10.1210/en.2005-1527
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
147/7/3623    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lam, E. Y. M.
Right arrow Articles by Young, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lam, E. Y. M.
Right arrow Articles by Young, M. J.
Endocrinology Vol. 147, No. 7 3623-3629
Copyright © 2006 by The Endocrine Society

Mineralocorticoid Receptor Blockade But Not Steroid Withdrawal Reverses Renal Fibrosis in Deoxycorticosterone/Salt Rats

Emily Y. M. Lam, John W. Funder, David J. Nikolic-Paterson, Peter J. Fuller and Morag J. Young

Prince Henry’s Institute of Medical Research (E.Y.M.L., J.W.F., P.J.F., M.J.Y.), Clayton, Victoria 3168, Australia; and Department of Nephrology (D.J.N.-P.), Monash University, Victoria 3800, Australia

Address all correspondence and requests for reprints to: Morag J. Young, Dr. Prince Henry’s Institute of Medical Research, Endocrine Genetics, P.O. Box 5152, Clayton, Victoria 3168, Australia. E-mail: morag.young{at}princehenrys.org.


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The pathophysiologic effects of nonepithelial mineralocorticoid receptor (MR) activation include vascular inflammation followed by renal and cardiac remodeling in experimental animals. We have recently shown that MR blockade can reverse established cardiac fibrosis and vascular inflammation; the present study explores whether a similar protection is seen in renal tissue. Rats were uninephrectomized and maintained on 0.9% NaCl solution to drink and treated as follows: control, vehicle; deoxycorticosterone (DOC), 20 mg/wk sc for 4 wk and then killed; DOC for 8 wk; DOC for 4 wk and no steroid for wk 5–8; DOC for 8 wk and eplerenone 100 mg/kg·d in the food for wk 5–8. DOC increased renal collagen at 4 and 8 wk; rats given DOC for 4 wk and killed at 8 wk showed levels of fibrosis identical with those killed at 4 wk, whereas rats given DOC for 8 wk plus eplerenone for wk 5–8 were indistinguishable from control. The inflammatory markers ED-1, osteopontin, and cyclooxygenase-2 remained significantly elevated despite the withdrawal of DOC (DOC404), whereas eplerenone restored cyclooxygenase-2 expression (but not that of ED-1 or osteopontin) to control levels. In addition, markers of oxidative stress and TGFß were determined. We hypothesize that continuing tubular inflammation and fibrosis despite DOC withdrawal indicates that the renal tissue may reflect MR activation in the context of tissue damage.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
ALDOSTERONE SECRETION is regulated by the renin-angiotensin system and plasma potassium levels. Aldosterone acts on renal principal cells of the distal nephron and the epithelial cells of the distal colon to modulate electrolyte homeostasis. This well-characterized response to mineralocorticoid receptor (MR) activation involves genomic regulation of aldosterone responses including serum and glucocorticoid inducible kinase 1 and the epithelial sodium channel subunits (1). MR activation has also been clearly demonstrated in nonepithelial tissues such as the heart, brain, and blood vessel wall (2, 3, 4). We (2, 3, 4) and others (5, 6) have shown that activation of these nonepithelial MR is followed by pathological tissue remodeling in the heart and kidney, independent of increases in systolic blood pressure or changes in electrolyte status.

Elevated plasma aldosterone in the context of a high sodium intake produces inflammation and oxidative stress in the blood vessel wall in the first instance, followed by tissue remodeling in both the heart and kidney (4, 7). Experimental models of mineralocorticoid administration [aldosterone or deoxycorticosterone (DOC)] plus salt may provide an insight into the mechanisms underlying the beneficial effects of MR blockade observed in recent large-scale clinical trials. In progressive cardiac failure, low-dose spironolactone was added to standard care in the Randomized ALdactone Evaluation Study (8); subsequently the selective MR antagonist eplerenone was similarly used in left ventricular dysfunction after myocardial infarction [Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and SUrvival Study (9). Recent preliminary data from clinical studies have shown that MR blockade protects the kidneys and in particular decreases proteinuria (9, 10). These effects appear independent of beneficial blood pressure effects and can protect patients from vascular injury associated with diabetes mellitus and hypertension (11, 12). In particular, eplerenone proved more effective than enalapril in reducing proteinuria in both patients with stage 1 or 2 congestive heart failure and essential hypertension (12).

Aldosterone has also been clearly shown to be a mediator of renal inflammation and fibrosis in rat models of mineralocorticoid/salt hypertension (7). Renal injury, as assessed by inflammatory markers and fibrosis, produces severe vascular and glomerular sclerosis, fibrinoid necrosis and thrombosis, interstitial leukocyte infiltration, and tubular damage with regeneration (13). Proinflammatory events are significantly reduced by coadministration of the selective MR antagonist eplerenone from d 0, indicating that inflammation is a key driver in aldosterone/salt-induced renal injury, as is the case in the heart. The progression of renal injury after an immune or nonimmune insult is closely associated with the accumulation of leukocytes and fibroblasts in the damaged kidney; macrophage accumulation is a prominent feature of most forms of human glomerulonephritis and correlates with renal dysfunction (14). Macrophages have also been shown to mediate acute and chronic renal injury in experimental kidney disease (15, 16).

Studies of the mineralocorticoid/salt model of tissue remodeling have predominantly addressed the preventive effects of MR blockade rather than reversal of established fibrosis. We have recently shown that the coronary vascular inflammation and cardiac fibrosis established by 4 wk of DOC treatment can be reversed by the MR selective blocker eplerenone but not mineralocorticoid withdrawal alone (17). The aim of the present studies was thus to determine whether the tissue inflammation and early tissue remodeling induced in the kidney by DOC/salt treatment can be similarly reversed.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
All protocols for animal use were approved by the Monash University Animal Ethics Committee. Male Sprague Dawley rats (190–210 g starting weight) were uninephrectomized under anesthesia with Ilium Xylazil (8 mg/kg; Troy Laboratories, Smithfield, New South Wales, Australia) and ketamine (60 mg/kg; Parke-Davis, Auckland, New Zealand) and carprofen (5 mg/kg, given once sc; Pfizer, New York, NY) for postoperative analgesia. Rats were then maintained on chow ad libitum and 0.9% NaCl solution to drink for the remainder of the study and randomly assigned to one of five treatment groups: 1) control, with no further treatment for 8 wk (CON, n = 8); 2) DOC, 20 mg in corn oil sc once a week from d 2 for 4 wk (DOC4, n = 7; Sigma, St. Louis, MO); 3) DOC as for group 2 but for 8 wk (DOC8, n = 7); 4) DOC for 4 wk, and then no treatment for 4 wk (DOC404, n = 8) and; 5) DOC for 8 wk plus eplerenone 100 mg/kg/d for wk 5–8 (DOC8EPL4, n = 8; Pfizer, St. Louis MO). Eplerenone was incorporated into the chow by Glenforest Stock Feeders (Glen Forest, Western Australia).

Animals were killed by CO2 in air at 8 wk, except for the DOC4 group, which was killed at 4 wk. Kidneys were excised, weighed, bisected, and half fixed in buffered 4% paraformaldehyde for 6 h at 4 C and then rinsed and stored overnight in PBS before processing for paraffin embedding. The remainder of the fresh tissue was snap frozen in liquid nitrogen and mRNA extracted for RT-PCR analysis. Serum was isolated from an arterial blood sample for determination of creatinine levels.

Histological analysis
Tissue blocks were sectioned at 5-µm thickness onto glass slides. Renal cortical collagen levels were determined by picrosirius red staining and analyzed by Analytical Imaging Systems software (Imaging Research, Inc., Piscataway, NJ). Immunochemistry for inflammatory cytokines and ED-1-positive macrophages was performed using antibodies as previously described for studies in the heart (9). Hemeoxygenase 1 (HO-1) immunostaining was performed on 5-µM sections and were dewaxed and rehydrated through graded alcohols before antigen retrieval by 10 min boiling in standard citrate retrieval buffer. They were then blocked sequentially in 0.3% H2O2 in Tris-buffered saline (TBS), avidin (0.001% in TBS), biotin (0.001% in TBS), and normal goat serum (10%) plus BSA (5%) before overnight incubation at 4 C with HO-1 primary antibody (1:2000 dilution in 5% goat and 10% rat serum; Stressgen, Ann Arbor, MI). On the second day, sections were washed 3 x 3 min in TBS and incubated with biotinylated goat antirabbit secondary antibody (1:200; Dako, Carpinteria, CA) for 45 min. Preincubated avidin biotin complex and filtered diaminobenzidine were applied before dehydration and mounting in Depex (BDH Merck, Poole, UK). Collagen content is expressed as percentage of area per field analyzed.

Expression of osteopontin, cyclooxygenase (COX)-2, and HO-1 was determined by unbiased systematic sampling to determine the average number of positively stained structures (i.e. tubules, collecting ducts) per field (osteopontin and HO-1) or the percent area of positively stained tissue (COX-2). Changes in ED-1 expression were estimated by determining the average number of positively stained macrophages per field. In the case of osteopontin, COX-2, and HO-1, the cells comprising positively stained tubules and collecting ducts were stained uniformly; negative structures showed no staining. At least 60 fields for osteopontin, COX-2, and HO-1 were analyzed and at least 80 ED-1-positive macrophages were counted for each rat to ensure sufficient numbers were sampled for the correct calculation of statistical significance. The counting frame used for analysis was 826,890 µm2. Mean values for each group were compared by one-way ANOVA with Tukey’s post hoc test.

RT-PCR
Total RNA was prepared from freshly isolated rat renal tissues (cortex) with Ultraspec (Fisher Biotec, West Perth, Australia) following the manufacturer’s instructions. First-strand cDNA synthesis from 500 ng total RNA was performed after DNase treatment with avian myeloblastosis virus reverse transcriptase (Roche, Stockholm, Sweden) primed by random hexamers. PCRs were carried out using the following primer sets (all 5' to 3'): p22phox sense, CCC CCG GGG AAA GAG GAA AA, antisense, GCA GGC GAC AGC ACT AAG; gp91phox sense, CCA TTC GGA GGT CTT ACT TTG, and antisense, CTG GGC ACT CCT TTA TTT TTC; NOX4, the nicotinamide adenine dinucleotide phosphate (reduced) [NAD(P)H] oxidase subunit 4, sense, GAA CCT CAA CTG CAG CCT GAT C and antisense, CCT TTG TCC AAC AAT CTT CTT GTT CTC. Expression levels were normalized to 18S rRNA levels: (18S sense, CGG CTA CCA CAT CCA AGG AA, antisense, GCT GGA ATT ACC GCC GCT). To validate the real-time PCR protocol, gene-specific standard curves for p22phox and ribosomal 18S were generated from 10-fold serial dilutions of pre-prepared standards. Standards were diluted as follows: from 10 to 0.1 pg/µl for 18S and from 500 fg/µl to 0.5 fg/ßl for all other transcripts. Real-time PCR amplification was performed on the Lightcycler (Roche Molecular Biochemicals, Mannheim, Germany) using SYBR Green reaction mix (Roche Molecular Biochemicals) and the primers described above. cDNA samples were diluted 1:20 in water immediately before use for p22phox and 18S; gp91phox and NOX-4 were analyzed undiluted. Relative amount of mRNA was calculated using the comparative crossing threshold method. All specific amplicons were normalized against housekeeping gene 18S whose expression was determined as an internal control using predeveloped assay reagents (Applied Biosystems, Foster City, CA). In addition, TGFß1 mRNA levels were analyzed by multiplex real-time RT-PCR on the Corbett Rotor-Gene using the following primers and probes: TGFß1 sense, GGA CAC ACA GTA CAG CAA; antisense, GAC CCA CGT AGT AGA CGA T; FAM-labeled MGB probe, ACA ACC AAC ACA ACC C; and the Vic-labeled 18S TaqMan rRNA Control (Applied Biosystems). Reactions were performed using the RealMasterMix (Eppendorf AG, Hamburg, Germany) and analyzed using the {Delta}{Delta}Ct ({Delta}{Delta} crossing threshold) method.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Eplerenone reverses renal interstitial fibrosis
To determine whether eplerenone can reverse established renal fibrosis, rats were treated with DOC for 8 wk, a time frame previously shown to be sufficient for the development of fibrosis, and given eplerenone for wk 5–8. DOC treatment alone produced a significant increase in perivascular and tubulointerstitial fibrosis as determined by Sirius red staining after 4 wk; at 8 wk the mean value was higher than that at 4 wk, although this was not significant on a population basis (Fig. 1Go). After steroid withdrawal, the extent of fibrosis was not significantly different from that seen with DOC treatment at either the 4- or 8-wk time points. The addition of eplerenone to continuing DOC administration from 5 to 8 wk reduced collagen to levels not different from control. Importantly, addition of eplerenone substantially and significantly reduced levels of fibrosis to half those seen in the DOC404 steroid withdrawal group.


Figure 1
View larger version (16K):
[in this window]
[in a new window]
 
FIG. 1. Perivascular and interstitial renal fibrosis. DOC for 4 (DOC4) or 8 (DOC8) wk significantly increased renal collagen content, compared with control (CON). Collagen levels remained elevated after steroid withdrawal (DOC404) but not MR blockade for wk 5–8 of DOC treatment (DOC8E8). P < 0.05 vs. CON; {dagger}, P < 0.05 vs. DOC4, DOC8, DOC404.

 
Markers of inflammation
The inflammatory markers ED-1-positive macrophages, osteopontin, and COX-2 are well-characterized indicators of tissue damage, and raised levels have been shown to precede the onset of tissue fibrosis (17, 18). We therefore examined the responses of these markers to eplerenone treatment for wk 5–8 of DOC administration. Figure 2Go shows values for ED-1 (Fig. 2AGo, top panel), COX-2 (Fig. 2Go, B and C), and osteopontin for each of the five groups of animals. Eplerenone showed different effects on each of the three inflammatory markers examined.


Figure 2
View larger version (16K):
[in this window]
[in a new window]
 
FIG. 2. Inflammatory marker expression of cortical region of the kidney in the DOC/salt rat as determined by stereology. Treatments as for Fig. 1Go; A, Increased staining for infiltrating macrophages was seen after DOC or 8 wk and steroid withdrawal (DOC404). B and C, COX-2 staining for outer cortex and inner cortex, respectively. DOC treatment for 4 (DOC4, inner cortex) and 8 wk (DOC8, inner and outer cortex) were significantly higher than control. Staining was also increased after steroid withdrawal in both areas of the cortex. MR blockade significantly reduced COX-2 expression after DOC treatment. D, Increased osteopontin staining the whole cortex at 4 and 8 wk of DOC. *, P < 0.05 vs. CON; {dagger}, P < 0.05 vs. DOC404.

 
In the present study, ED-1-positive macrophage infiltration in the cortex was significantly increased above control after 8 wk, with or without steroid withdrawal; eplerenone from wk 5 to 8 did not produce a significant reduction in number.

COX-2 expression showed similar responses in both the outer and inner cortex (Fig. 2Go, B and C) to those in the heart (17). Significant increases were seen after 4 and 8 wk of DOC treatment and in the steroid withdrawal group in the inner and outer cortex of the kidney, with eplerenone reducing expression back to control levels. The renal medulla was also evaluated and showed no significant changes in COX-2 expression in tubules or collecting ducts in any of the groups (data not shown).

For osteopontin (Fig. 2DGo), the values at 4 and 8 wk of DOC and after steroid withdrawal were all significantly elevated above control, in a pattern similar to that seen in the cardiac vasculature; no significant differences were seen between these groups. Whereas both the steroid withdrawal group and the eplerenone treatment group appeared to be also elevated above control, this did not reach significance. However, these groups were also not different from the DOC treatment groups.

In the present study, we also determined mRNA expression of TGFß1 in whole kidney by quantitative RT-PCR. DOC administered for 4 wk markedly and significantly elevated mRNA expression above control (Fig. 3DGo); levels of TGFß1 were not different from control in the other treatment groups. Thus, eplerenone treatment appears to reverse the DOC-induced increase in some but not all markers of inflammation in the renal cortex.


Figure 3
View larger version (15K):
[in this window]
[in a new window]
 
FIG. 3. NAD(P)H oxidase subunit mRNA expression relative to 18s rRNA. Treatments as for Fig. 1Go; for panels A–C, values after DOC for 8 wk were elevated, whereas for panels A and B they are also elevated at 4 wk of treatment and after steroid withdrawal. Cotreatment with eplerenone reversed DOC-mediated changes to control levels. Panel D shows a significant transient increase in TGFß1 mRNA expression at 4 wk of DOC. * P < 0.05 vs. CON; {dagger} P < 0.05 vs. DOC404.

 
Markers of oxidative stress
mRNA expression.
We examined the mRNA expression pattern of subunits of nicotinamide adenine dinucleotide phosphate (reduced) [NAD(P)H] oxidase. Figure 3Go, A–C, shows mRNA expression of components of the NADPH oxidase system implicated in the generation of reactive oxygen species in the five experimental groups, showing a commonality of response. For the widely expressed p22phox (Fig. 3Go, top panel), mean values are similarly increased at 4 and 8 wk and at 4 wk after DOC withdrawal (DOC404), with those after 8 wk DOC not further elevated by ANOVA; values in animals receiving eplerenone over the last 4 wk (DOC8E4) returned to control levels. Very similar patterns of response are seen for gp91phox (center panel), whereas the NOX-4 subunit (third panel), which is expressed at high levels in the kidney, is markedly elevated at 8 wk of DOC and shows small but commensurate increases in mean levels at 4 wk and in the steroid withdrawal group.

HO-1.
Expression of HO-1 was restricted to the outer cortex and was found predominantly in distal and proximal tubules. However, whereas staining was also seen in the blood vessels and medulla region of DOC-treated animals, the level of staining was not sufficient to be quantified by stereological methods. Figure 4Go shows HO-1 staining in the cortex for each of the treatment groups. DOC treatment for either 4 or 8 wk significantly (P < 0.05) increased HO-1 staining; levels were sustained after steroid withdrawal but returned to control values with MR blockade.


Figure 4
View larger version (17K):
[in this window]
[in a new window]
 
FIG. 4. HO-1. Treatments as for Fig. 1Go; treatment with DOC for 4 or 8 wk significantly increased HO-1 expression, whereas cotreatment with eplerenone, but not steroid withdrawal, reversed DOC-mediated changes to control levels. *, P < 0.05 vs. CON and DOC8EPL4.

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
We have previously shown that MR blockade in a model of established (4 wk treatment with DOC) coronary vascular inflammation and cardiac fibrosis reverses collagen accumulation and markers of inflammation and oxidative stress (17). These changes were not reproduced at 8 wk by steroid withdrawal at the 4-wk time point, suggesting that the inflammatory events established by DOC administration allow ongoing activation of the MR in the absence of elevated plasma mineralocorticoid. In the present studies, we have established the pattern of response to reversal after eplerenone treatment in the kidney, another tissue clearly affected by mineralocorticoid/sodium imbalance.

In the present study, we showed that 8 wk of DOC treatment in conjunction with a high-salt diet produces increased collagen deposition in the tubulointerstitial spaces. Moreover, when DOC is withdrawn at 4 wk, collagen levels remain significantly elevated. MR activation in the presence of a high-salt intake has been shown to cause renal injury and fibrosis in several experimental models, including stroke-prone, spontaneously hypertensive rats (19), angiotensin II infused/saline drinking rats (20), and N-omega-nitro-L-arginine methyl ester/angiotensin II-treated rats (13). In these models MR blockade or adrenalectomy reduces proteinuria and prevents fibrinoid necrosis of renal vessels and interstitial tissues. Similarly, MR activation has been shown to contribute to the tubulointerstitial damage and fibrosis that accompanies unilateral ureteral obstruction, in that the MR antagonist spironolactone can prevent tissue remodeling in this model (21).

These models have been shown to involve common inflammatory responses such as macrophage infiltration and cytokine up-regulation (7). In particular, osteopontin, which is expressed at low levels in the kidney under normal conditions, is clearly up-regulated and expressed more broadly. We found osteopontin expression, as determined by immunohistochemistry, in the thick ascending loop of Henle, proximal tubules, and some glomeruli in response to DOC/salt administration for 8 wk. Osteopontin expression remained elevated after steroid withdrawal and, in contrast with the heart, was not reversed by eplerenone (17). Given the clear increase in osteopontin expression in a range of renal disease models, it is possible that increased expression was exacerbated by uninephrectomy and thus that our results reflect not only MR activation but also non-MR responses.

Macrophages are the predominant infiltrating inflammatory cells recruited to the kidney in models of renal injury and may also produce proinflammatory cytokines to increase tissue damage and fibrosis. Macrophage infiltration is regarded as an indicator of tissue damage in experimental animals and clinical renal biopsies (14). Several authors have demonstrated that increased renal production of chemoattractants, such as osteopontin and monocyte chemoattractant protein-1, plays a functional role in renal macrophage accumulation and tissue damage (22, 23, 24). In the current study, ED-1-positive macrophages were detected in the interstitial space, around blood vessels, and within glomeruli of animals treated with DOC. Macrophage numbers were significantly up-regulated in the kidneys of DOC-treated animals and followed a similar pattern of expression to that of osteopontin (Fig. 2Go), in that MR activation increased levels but neither steroid withdrawal nor eplerenone treatment produced a significant reduction, supporting the causal link between osteopontin and macrophage recruitment. These findings again differ, however, from the ED-1 expression pattern determined in the heart (17), in which expression was significantly elevated after both 4 and 8 wk of DOC and returned to control values after eplerenone treatment for wk 5–8. These differences may reflect the underlying cellular changes that occur in the remaining kidney independent of administered DOC. One other possibility is that the infiltrating macrophages seen in the eplerenone-treated kidney are involved in the resolution of renal damage. It is known that macrophages can actively promote tissue repair as well as cause damage (25). Therefore, MR blockade may have changed the activation status of the infiltrating renal macrophages from a state of promoting renal fibrosis to one of promoting renal repair. Further studies are required to investigate this possibility.

COX-2 is an inducible enzyme and under normal conditions is expressed at low or undetectable levels. It is, however, normally expressed in the kidney, predominantly in the macula densa but also in the thick ascending loop of Henle. Increased COX-2 expression has been associated with a number of renal disease states in which expression is detected in a wide range of tissue structures. We identified renal tubule and collecting duct changes in COX-2 expression and found that significant changes were detected only in the renal cortex. The cortical pattern of response in both the inner and outer regions was similar to that in heart, with expression levels clearly elevated after steroid withdrawal and eplerenone treatment returning levels to control values (Fig. 2Go, B and C). The observation that steroid withdrawal alone does not effectively reverse the observed changes in the tubules and collecting duct of the kidney cortex suggests that sustained renal damage allows continued activation of the MR; a similar pattern of COX-2 expression was found in the heart. Given that the pattern of response for renal interstitial fibrosis is similar to that for COX-2 but not for the other inflammatory markers, COX-2, and the production of prostaglandins may thus be a tissue-specific signaling mechanism for the induction of renal damage and fibrosis. The beneficial effects of COX-2 inhibitors in the kidney under some circumstances (26) provide further support for this hypothesis and, given that similar protection is not seen in the heart (27), further demonstrate that overlapping but not identical mechanisms may operate in the development of fibrosis in these tissues.

In this study we also determined for the first time changes in expression of mRNA levels for specific markers of increased NAD(P)H oxidase activity in the kidney. Given that isoforms of the membrane bound NOX subunit of the NAD(P)H oxidase complex are expressed in a tissue-specific manner, our results indicate that there may also be cell-specific regulation of the oxidative stress response. The gp91phox isoform (NOX-2) is predominantly expressed in endothelial cells and infiltrating macrophages and is markedly up-regulated by DOC from 4 wk. Expression of this subunit did not fall after steroid withdrawal, suggesting ongoing production of superoxide ions in these cells types, which may contribute to the sustained inflammatory response. In contrast, expression of the NOX-4 isoform is only slightly increased after DOC for 4 wk but markedly elevated at 8 wk of treatment, with levels after steroid withdrawal comparable with those after 4 wk of steroid treatment. The NOX-4 isoform is expressed not only in the vasculature but also extensively in the renal epithelium; the higher abundance of epithelial cells in the kidney than the heart implies that the values recorded are likely to reflect changes in the renal tubules rather than the vascular wall as is the case in the heart. For example, MR activation has recently been shown to produce oxidative stress in tissues other than the vessel wall (28, 29), and in cultured rat mesangial cells, aldosterone increases localization of the cytosolic NAD(P)H subunits to the membrane (30). Similar patterns of subunit mRNA expression were detected in the heart, suggesting that along with COX-2 expression, oxidative stress may be a common factor in translating MR signaling into vascular inflammation and tissue remodeling in these different tissues.

HO-1 is increased by oxidative stress and is a well-accepted marker of oxidative stress in the kidney. It has been used in the current study to both support the mRNA oxidative stress data and provide an indication of the cell types involved in the oxidative stress response. Staining was predominantly seen in the proximal and distal tubules of the cortex and was confined to the outer cortex in control and eplerenone-treated animals. The HO-1 staining supports the NOX-4 in particular, given that the tubular epithelium is a predominant site of NOX-4 expression. It is also important to note that the pattern of staining for the immunostaining is different from that for mRNA expression of the NAD(P)H oxidase subunits. Whereas the mRNA expression is significantly reduced after both steroid withdrawal and MR blockade, the HO-1 staining remained significantly elevated in the steroid withdrawal group, indicating that whereas the NAD(P)H oxidase subunit expression is reduced, oxidative stress is still present. Without protein data for NAD(P)H oxidase, it is unclear as to the underlying cellular mechanisms that are responsible for the sustained oxidative response in this study.

An important consideration in understanding MR signaling is the maintenance of MR specificity by the enzyme 11ß-hydroxysteroid dehydrogenase type 2 (11ßHSD2) (31). Whereas vascular sites of MR expression are protected by 11ßHSD2 activity, cardiac myocytes are not, indicating that several levels of regulation of MR signaling may exist in the cardiovascular system (17, 32). We have shown that glucocorticoids can activate vascular MR when 11ßHSD2 is blocked, and this results in similar inflammatory and fibrotic responses to aldosterone excess (4). Similarly, Ward et al. (33) showed that eplerenone blocked coronary fibrosis and constriction after angioplasty in normal pigs, which suggests that the MR may be activated in the absence of administered salt and/or mineralocorticoid in the context of tissue damage. Tissue damage or 11ßHSD2 blockade leading to altered intracellular redox state has thus been proposed to activate glucocorticoid occupied MR, promoting the progression of vascular damage, even when plasma aldosterone levels are not elevated (34).

The current study compares tissue responses with either receptor blockade or steroid withdrawal in a model of renal fibrosis and thus differs from many other studies that investigate models of prevention. That established pathology can be reversed by MR blockade has been recently shown by the 4E Left Ventricular Study (35), which demonstrated the ability of eplerenone, enalapril, or the two in combination to reverse left ventricular hypertrophy in essential hypertensives. Whereas there was also a reduction in blood pressure, this correlated poorly with hypertrophy, indicating the involvement of other factors in progression and maintenance of cardiac hypertrophy. Taken together these studies strongly suggest that tissue remodeling in the kidney and heart is a dynamic process that may be reversed if MR activation is a part the pathologic stimulus.


    Footnotes
 
Disclosure statement: E.Y.M.L. has nothing to declare. D.J.N.-P. has received support from Johnson and Johnson, but this is unrelated to the current project. J.W.F. has received consulting fees from Merck, Pfizer, Sankyo, Lilly, Schering-Plough, Wyeth, Excelisis, and CBio. P.J.F. has received consulting fees from Merck and lecture fees from Novartis. M.J.Y., P.J.F., and J.W.F. have been the recipients of a previous research grant from Pfizer Inc. and M.J.Y. and J.W.F. from Merck. The present study does not relate to these activities.

First Published Online April 20, 2006

Abbreviations: COX, Cyclooxygenase; DOC, deoxycorticosterone; HO-1, hemeoxygenase 1; 11ßHSD2, 11ß-hydroxysteroid dehydrogenase type 2; MR, mineralocorticoid receptor; NAD(P)H, nicotinamide adenine dinucleotide phosphate (reduced); NOX-4, NAD(P)H oxidase subunit 4; TBS, Tris-buffered saline.

Received December 5, 2005.

Accepted for publication April 12, 2006.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Fuller PJ, Young MJ 2005 Mechanisms of mineralocorticoid action. Hypertension 46:1227–1235[Abstract/Free Full Text]
  2. Young M, Fullerton M, Dilley R, Funder J 1994 Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 93:2578–2583[Medline]
  3. Young M, Head G, Funder J 1995 Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 269:E657–E662
  4. Young MJ, Moussa L, Dilley R, Funder JW 2003 Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11ß-hydroxysteroid dehydrogenase inactivation. Endocrinology 144:1121–1125[Abstract/Free Full Text]
  5. Rocha R, Chander PN, Zuckerman A, Stier Jr CT 1999 Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33:232–237[Abstract/Free Full Text]
  6. Brilla CG, Weber KT 1992 Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 120:893–901[Medline]
  7. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG 2003 Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63:1791–1800[CrossRef][Medline]
  8. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709–717[Abstract/Free Full Text]
  9. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatin M, and the Eplerenone Post-Acute Myocardial Infarction Heart Failure, Efficacy Survival Study Investigators 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med [Erratum (2003) 348:2271] 348:1309–1321[CrossRef]
  10. Epstein M 2003 Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Nephrol Dial Transplant 18:1984–1992[Free Full Text]
  11. Hollenberg NK 2004 Aldosterone in the development and progression of renal injury. Kidney Int 66:1–9[CrossRef][Medline]
  12. Williams GH, Burgess E, Kolloch RE, Ruilope LM, Niegowska J, Kipnes MS, Roniker B, Patrick JL, Krause SL 2004 Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 93:990–996[CrossRef][Medline]
  13. Rocha R, Stier Jr CT, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK 2000 Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141:3871–3878[Abstract/Free Full Text]
  14. Nikolic-Paterson DJ, Atkins RC 2001 The role of macrophages in glomerulonephritis. Nephrol Dial Transplant 16:3–7[Abstract/Free Full Text]
  15. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollins BJ, Tesch GH 2006 Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 69:73–80[CrossRef][Medline]
  16. Ikezum Y, Hurst LA, Masaki T, Atkins RC, Nikolic-Paterson DJ 2003 Adoptive transfer studies demonstrate that macrophages can induce proteinuria and mesangial cell proliferation. Kidney Int 63:83–95[Medline]
  17. Young MJ, Funder JW 2004 Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats. Endocrinology 145:3153–3157[Abstract/Free Full Text]
  18. Rocha R, Rudolph AE, Frierdich GE, Nochowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA 2002 Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283:H1802–H1810
  19. Endemann DH, Touyz RM, Iglarz M, Savoia C, Schiffrin EL 2004 Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 43:1252–1257[Abstract/Free Full Text]
  20. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E 2002 Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 143:4828–4836[Abstract/Free Full Text]
  21. Trachtman H, Weiser AC, Valderrama E, Morgado M, Palmer LS 2004 Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction. J Urol 172:1590–1594[Medline]
  22. Lloyd CM, Minto AW, Dorf ME, Proudfoot A, Wells TN, Salant DJ, Gutierrez-Ramos JC 1997 RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 185:1371–1380[Abstract/Free Full Text]
  23. Rovin BH, Doe N, Tan LC 1996 Monocyte chemoattractant protein-1 levels in patients with glomerular disease. Am J Kidney Dis 27:640–646[Medline]
  24. Yu XQ, Nikolic-Paterson DJ, Mu W, Giachelli CM, Atkins RC, Johnson RJ, Lan HY 1998 A functional role for osteopontin in experimental crescentic glomerulonephritis in the rat. Proc Assoc Am Physicians 110:50–64[Medline]
  25. Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, Wu S, Lang R, Iredale JP 2005 Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 115:56–65[CrossRef][Medline]
  26. Cheng HF, Harris RC 2005 Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr Pharm Des 11:1795–1804[CrossRef][Medline]
  27. Krotz F, Schiele TM, Klauss V, Sohn HY 2005 Selective COX-2 inhibitors and risk of myocardial infarction. J Vasc Res 42:312–324[CrossRef][Medline]
  28. Iglarz M, Touyz RM, Viel EC, Amiri F, Schiffrin EL 2004 Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction with the renin-angiotensin system. Am J Hypertens 17:597–603[Medline]
  29. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M 2004 Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 109:2213–2220[Abstract/Free Full Text]
  30. Nishiyama A, Abe Y 2004 Aldosterone and renal injury. Nippon Yakurigaku Zasshi 124:101–109[Medline]
  31. Funder JW, Pearce PT, Smith R, Smith AI 1988 Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242:583–585[Abstract/Free Full Text]
  32. Myles K, Funder JW 1996 Progesterone binding to mineralocorticoid receptors: in vitro and in vivo studies. Am J Physiol 270:E601–E607
  33. Ward MR, Kanellakis P, Ramsey D, Funder J, Bobik A 2001 Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 104:467–472[Abstract/Free Full Text]
  34. Funder JW 2005 RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 93:121–125[CrossRef][Medline]
  35. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH 2003 Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108:1831–1838[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
HypertensionHome page
N. J. Brown
Aldosterone and Vascular Inflammation
Hypertension, February 1, 2008; 51(2): 161 - 167.
[Full Text] [PDF]


Home page
EndocrinologyHome page
A. J. Rickard, J. W. Funder, J. Morgan, P. J. Fuller, and M. J. Young
Does Glucocorticoid Receptor Blockade Exacerbate Tissue Damage after Mineralocorticoid/Salt Administration?
Endocrinology, October 1, 2007; 148(10): 4829 - 4835.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
147/7/3623    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lam, E. Y. M.
Right arrow Articles by Young, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lam, E. Y. M.
Right arrow Articles by Young, M. J.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals